Amneal Pharmaceuticals, Inc.(AMRX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #957 of 2,879 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
AMRX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Amneal Pharmaceuticals, Inc. (AMRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AMRX at 58.9/100 on a 32-signal composite quality model, placing it at rank #957 of 2,879 stocks — the top half of the AI-ranked universe. Areas of concern include earnings quality (30.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), Amneal Pharmaceuticals, Inc. reports quarterly revenue of $722.5M, net income of $62.3M, free cash flow of $-34.9M. Top institutional holders of AMRX by reported 13-F value include BlackRock,, TPG GP A,, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. AMRX trades on the Nasdaq exchange and files with the SEC under CIK 1723128. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AMRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Amneal Pharmaceuticals, Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$722.5M
Net Income
Q1 2026
$62.3M
Free Cash Flow
Q1 2026
$-34.9M
Get alerted when AMRX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Amneal Pharmaceuticals, Inc. including:
Top Institutional Holders of AMRX
BlackRock, Inc.
$304.8M24,519,192 shTPG GP A, LLC
$153.2M12,328,767 shVANGUARD PORTFOLIO MANAGEMENT LLC
$140.8M11,324,933 shRubric Capital Management LP
$137.2M11,037,589 shVANGUARD CAPITAL MANAGEMENT LLC
$94.3M7,585,034 shSTATE STREET CORP
$84.5M6,794,702 shDIMENSIONAL FUND ADVISORS LP
$70.7M5,690,586 shMORGAN STANLEY
$57.6M4,637,185 shGEODE CAPITAL MANAGEMENT, LLC
$56.5M4,546,048 shNeuberger Berman Group LLC
$45.7M3,682,284 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $304.8M | 24,519,192 |
| TPG GP A, LLC | $153.2M | 12,328,767 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $140.8M | 11,324,933 |
| Rubric Capital Management LP | $137.2M | 11,037,589 |
| VANGUARD CAPITAL MANAGEMENT LLC | $94.3M | 7,585,034 |
| STATE STREET CORP | $84.5M | 6,794,702 |
| DIMENSIONAL FUND ADVISORS LP | $70.7M | 5,690,586 |
| MORGAN STANLEY | $57.6M | 4,637,185 |
| GEODE CAPITAL MANAGEMENT, LLC | $56.5M | 4,546,048 |
| Neuberger Berman Group LLC | $45.7M | 3,682,284 |
More Healthcare Companies
View all Healthcare →Put AMRX on your watchlist
Track score changes the day Amneal Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AMRX a good stock to buy?
13F Pro's AI-powered analysis of Amneal Pharmaceuticals, Inc. (AMRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AMRX are available on the AMRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own AMRX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AMRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Amneal Pharmaceuticals, Inc.'s investment landscape.